Anti-C5a antibody IFX-1 (vilobelimab) treatment versus best supportive care for patients with severe COVID-19 (PANAMO): an exploratory, open-label, phase 2 randomised controlled trial

Vlaar, APJ; de Bruin, S; Busch, M; Timmermans, SAMEG; van Zeggeren, IE; Koning, R; ter Horst, L; Bulle, EB; van Baarle, FEHP; van de Poll, MCG; Kemper, EM; van der Horst, ICC; Schultz, MJ; Horn, J; Paulus, F; Bos, LD; Wiersinga, WJ; Witzenrath, M; Rueckinger, S; Pilz, K; Brouwer, MC; Guo, RF; Heunks, L; van Paassen, P; Riedemann, NC; van de Beek, D

Vlaar, APJ (corresponding author), Univ Amsterdam, Amsterdam UMC, Dept Intens Care, NL-1100 DD Amsterdam, Netherlands.

LANCET RHEUMATOLOGY, 2020; 2 (12): E764

Abstract

Background Severe COVID-19 is characterised by inflammation and coagulation in the presence of complement system activation. We aimed to explore the p......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索